Quantitative determination method for specific IgG antibody in plasma

Abstract

The invention discloses a quantitative determination method for a specific IgG antibody in plasma, which belongs to the field of antibody detection. The method comprises the following steps of 1) dividing one plasma sample into two groups as to-be-detected plasma and to-be-treated contrast plasma, (2) incubating excessive antigens and to-be-treated contrast plasma, and neutralizing to-be-detected antibodies in the to-be-treated contrast plasma to obtain contrast plasma, 3) taking to-be-detected plasma and contrast plasma as samples, combining the to-be-detected plasma and the contrast plasma with corresponding antigens connected to the solid-phase carrier, successively combining the antigen-antibody compound with IgG antibodies and signal molecules to generate quantifiable data, and subtracting two groups of quantifiable data to obtain detection data, 4) diluting thousands of mixed plasma serving as a standard substance into different concentrations according to the steps 1)-3) to make a standard curve, and 5) substituting detection data of a to-be-detected sample into the standard curve to obtain the content of the specific IgG antibody in the plasma. According to the determination method, the influence of non-specific binding can be eliminated, and the detection result is reliable.

Description

Technical field [0001] The invention belongs to the field of antibody detection. Background technique [0002] Alzheimer's Disease (AD) is a common central nervous system degenerative disease with the main characteristics of memory cognitive function, which mainly clinically manifested the deletion of memory capabilities and the decline in cognitive function. The main pathological features are extracellular β-amylin, AmyiD β-Protein, Aβ) precipitation, Neurofibrillary Tangles, NFTS and a large number of apoptosis and loss of neuronal neurons. According to these pathological features, a variety of pathogenic hypothesis, in the explanation of many of the pathogenesis of AD, is currently "A [beta] cascaded holiday", which believes that the occurrence of AD is due to the formation of Aβ in vivo The metabolic imbalance was eliminated, so that it was deposited in a particular brain to form an elderly spot, and further triggered Tau protein to form NFTS, which eventually led to sudden l...

AI Technical Summary

Problems solved by technology

This method has great limitations: First, the components in the plasma are complex, and some substances other than the Aβ antibody will bind to the coated Aβ non-specifically, resulting in false positive results and affecting the detection accuracy

However, these methods can only reduce non-specific binding or increase specific binding to a certain extent, but none of them can avoid the impact of non-specific binding on the detection results.

Images